Table 3.
CBC parameters (mean ± 1 SD) before and after treatment of male beagle dogs with Melox-SR (0.6 mg/kg SC)
| Parameter | Baseline | After treatment | Reference range |
| Hgb (g/dL) | 16.0 ± 0.7 | 16.8 ± 0.4 (16.7) | 13–20 |
| Hct (%) | 45.5 ± 2.6 | 49.2 ± 1.3 (51) | 40–55 |
| RBC (106/µL) | 6.9 ± 0.3 | 7.2 ± 0.4 (8.0) | 5.5–8.5 |
| MCV (fL) | 66.8 ± 2.1 | 67.8 ± 2.3 (64) | 62–74 |
| RDW (%) | 13.0 ± 0.4 | 12.4 ± 1.1 (15) | 12–15 |
| MCHC (g/dL) | 35.0 ± 0.6 | 34.2 ± 0.6 (33) | 33–36 |
| Platelets (×103/µL) | 363 ± 85 | 334 ± 68 (359) | 200–500 |
| MPV (fL) | 9.2 ± 1.1 | 10.4 ± 1.5 (14.4) | 7.5–14.6 |
| Nucleated cells (×103/µL) | 8.6 ± 2.3 | 8.7 ± 2.2 (10.3) | 4.5–15 |
| Neutrophils (×103/µL) | 5.8 ± 1.5 | 5.12 ± 1.9 (7.2) | 2.6–11 |
| Lymphocytes (×103/µL) | 1.8 ± 0.5 | 2.6 ± 0.6 (1.9) | 1–4.8 |
| Monocytes (×103/µL) | 0.5 ± 0.2 | 0.5 ± 0.2 (0.8) | 0.2–1.0 |
| Eosinophils (×103/µL) | 0.5 ± 0.3 | 0.5 ± 0.3 (0.1) | 0.1–1.2 |
| Basophils (×103/µL) | 0.03 ± 0.07 | 0.04 ± 0.01 (0) | 0–0.1 |
Baseline values are averaged from all 6 dogs, whereas posttreatment parameters (blood collected 48 h after Melox-SR administration) are averaged from the 5 dogs without clinical symptoms. Posttreatment parameters within parentheses are from the dog with clinical signs of melena, inappetence, and lethargy after administration of Melox-SR and diagnosed with leiomyosarcoma.